Geoffrey A Strange

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/861509/publications.pdf

Version: 2024-02-01

54 papers 1,526 citations

361045 20 h-index 37 g-index

57 all docs

57 docs citations

57 times ranked

1699 citing authors

#	Article	IF	CITATIONS
1	Poor Long-Term Survival in Patients With Moderate Aortic Stenosis. Journal of the American College of Cardiology, 2019, 74, 1851-1863.	1.2	255
2	Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart, 2012, 98, 1805-1811.	1.2	237
3	Time from Symptoms to Definitive Diagnosis of Idiopathic Pulmonary Arterial Hypertension: The Delay Study. Pulmonary Circulation, 2013, 3, 89-94.	0.8	102
4	Threshold of Pulmonary Hypertension Associated With Increased Mortality. Journal of the American College of Cardiology, 2019, 73, 2660-2672.	1.2	80
5	Ejection fraction and mortality: a nationwide registerâ€based cohort study of 499 153 women and men. European Journal of Heart Failure, 2021, 23, 406-416.	2.9	62
6	Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA). European Heart Journal Cardiovascular Imaging, 2021, 22, 505-515.	0.5	60
7	Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: initial experience with the ADAPT-treated CardioCel(R) patch. Interactive Cardiovascular and Thoracic Surgery, 2013, 17, 698-702.	0.5	57
8	Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. Respirology, 2020, 25, 863-871.	1.3	46
9	The National Echocardiography Database Australia (NEDA): Rationale and methodology. American Heart Journal, 2018, 204, 186-189.	1.2	45
10	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. European Respiratory Journal, 2020, 56, 2000008.	3.1	38
11	Bosentan therapy in patients with pulmonary arterial hypertension: The relationship between improvements in 6 minute walk distance and quality of life. Respirology, 2008, 13, 674-682.	1.3	31
12	Adverse Prognostic Impact of Even Mild or Moderate Tricuspid Regurgitation: Insights from the National Echocardiography Database of Australia. Journal of the American Society of Echocardiography, 2022, 35, 810-817.	1.2	30
13	Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Heart Lung and Circulation, 2018, 27, 1368-1375.	0.2	26
14	An evaluation of Admedus' tissue engineering process-treated (ADAPT) bovine pericardium patch (CardioCel) for the repair of cardiac and vascular defects. Expert Review of Medical Devices, 2015, 12, 135-141.	1.4	25
15	Trileaflet aortic valve reconstruction with a decellularized pericardial patch in a sheep model. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1167-1174.	0.4	24
16	Enhanced Diagnosis of Severe Aortic Stenosis Using Artificial Intelligence: AÂProof-of-Concept Study of 530,871ÂEchocardiograms. JACC: Cardiovascular Imaging, 2020, 13, 1087-1090.	2.3	24
17	Poor Survival with Impaired Valvular Hemodynamics After Aortic Valve Replacement: The National Echo Database Australia Study. Journal of the American Society of Echocardiography, 2020, 33, 1077-1086.e1.	1.2	24
18	Congenital Heart Disease Requires a Lifetime Continuum of Care: A Call for a Regional Registry. Heart Lung and Circulation, 2016, 25, 750-754.	0.2	23

#	Article	IF	CITATIONS
19	Retrospective Validation of the REVEAL 2.0ÂRisk Score With the Australian and NewÂZealand Pulmonary Hypertension Registry Cohort. Chest, 2020, 157, 162-172.	0.4	23
20	Prognostic impact of pulmonary arterial hypertension: A population-based analysis. International Journal of Cardiology, 2008, 124, 183-187.	0.8	20
21	Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 150-156.	0.3	19
22	Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. Heart, 2018, 104, 732-737.	1.2	19
23	Change in ejection fraction and <scp>longâ€term</scp> mortality in adults referred for echocardiography. European Journal of Heart Failure, 2021, 23, 555-563.	2.9	19
24	Cardiac Damage Staging Classification Predicts Prognosis in All the Major Subtypes of Severe Aortic Stenosis: Insights from the National Echo Database Australia. Journal of the American Society of Echocardiography, 2021, 34, 1137-1147.e13.	1.2	18
25	The manifestations of vasculopathy in systemic sclerosis and its evidenceâ€based therapy. International Journal of Rheumatic Diseases, 2009, 12, 192-206.	0.9	17
26	Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. European Respiratory Journal, 2020, 56, 1901654.	3.1	15
27	Incident aortic stenosis in 49 449 men and 42 229 women investigated with routine echocardiography. Heart, 2022, 108, 875-881.	1.2	15
28	Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?. BMC Cardiovascular Disorders, 2010, 10, 9.	0.7	14
29	Living With, and Caring for, Congenital Heart Disease in Australia: Insights From the Congenital Heart Alliance of Australia and New Zealand Online Survey. Heart Lung and Circulation, 2020, 29, 216-223.	0.2	14
30	Uncovering the treatable burden of severe aortic stenosis in Australia: current and future projections within an ageing population. BMC Health Services Research, 2021, 21, 790.	0.9	14
31	Prevalence and Outcomes of Lowâ€Gradient Severe Aortic Stenosis—From the National Echo Database of Australia. Journal of the American Heart Association, 2021, 10, e021126.	1.6	14
32	Transvalvular jet velocity, aortic valve area, mortality, and cardiovascular outcomes. European Heart Journal Cardiovascular Imaging, 2022, 23, 601-612.	0.5	12
33	Markers of Elevated Left Ventricular Filling Pressure Are Associated with Increased Mortality in Nonsevere Aortic Stenosis. Journal of the American Society of Echocardiography, 2021, 34, 465-471.	1.2	11
34	Uncovering the treatable burden of severe aortic stenosis in the UK. Open Heart, 2022, 9, e001783.	0.9	11
35	Left Heart Disease and Pulmonary Hypertension: Are We Seeing the Full Picture?. Heart Lung and Circulation, 2018, 27, 301-309.	0.2	10
36	Adult Congenital Heart Disease in Australia and New Zealand: A Call for Optimal Care. Heart Lung and Circulation, 2019, 28, 521-529.	0.2	9

#	Article	IF	CITATIONS
37	The challenge of an expanded therapeutic window in pulmonary hypertension. Nature Reviews Cardiology, 2020, 17, 195-197.	6.1	9
38	Increasing risk of mortality across the spectrum of aortic stenosis is independent of comorbidity & Los ONE, 2022, 17, e0268580.	1.1	8
39	Integrated care and optimal management of pulmonary arterial hypertension. Journal of Multidisciplinary Healthcare, 2009, 2, 67.	1.1	7
40	National and regional registries for congenital heart diseases: Strengths, weaknesses and opportunities. International Journal of Cardiology, 2021, 338, 89-94.	0.8	6
41	Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 253-263.	0.7	5
42	Prevalence and Cost of Managing Paediatric Cardiac Disease in Queensland. Heart Lung and Circulation, 2021, 30, 254-260.	0.2	5
43	Preserved ejection fraction and structural heart disease in 446Â848 patients investigated with echocardiography. ESC Heart Failure, 2021, 8, 1687-1690.	1.4	4
44	Moderate aortic stenosis: culprit or bystander?. Open Heart, 2022, 9, e001743.	0.9	4
45	Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National Echocardiographic Database of Australia. Journal of Clinical Medicine, 2021, 10, 4503.	1.0	3
46	Characteristics of Bicuspid Aortic Valve Disease and Stenosis: The National Echo Database of Australia. Journal of the American Heart Association, 2021, 10, e020785.	1.6	3
47	Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the <scp>PHSANZ</scp> registry. Respirology, 2021, 26, 1171-1180.	1.3	3
48	Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges. Heart Lung and Circulation, 2020, 29, 1459-1468.	0.2	2
49	Towards a Unified Coding System for Congenital Heart Diseases. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008216.	0.9	2
50	Top End Pulmonary Hypertension Study: Understanding Epidemiology, Therapeutic Gaps and Prognosis in Remote Australian Setting. Heart Lung and Circulation, 2021, 30, 507-515.	0.2	1
51	Non-parenteral Therapy for Pulmonary Arterial Hypertension: A Review of Efficacy, Tolerability and Factors Related to Patient Adherence. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S2689.	0.4	0
52	Reply. Journal of the American College of Cardiology, 2020, 75, 838-839.	1.2	0
53	Abstract 10885: Decreased Hydraulic Force Contributes to Diastolic Dysfunction and Associates with Survival Beyond Conventional Measures of Diastolic Dysfunction. Circulation, 2021, 144, .	1.6	0
54	Abstract 10869: Using All-Cause Mortality to Determine the Best Method for Indexation of Echocardiographic Measures According to Body Size in Obese and Non-Obese Patients. Circulation, 2021, 144, .	1.6	O